-
公开(公告)号:US11149037B2
公开(公告)日:2021-10-19
申请号:US16615746
申请日:2018-05-22
Applicant: H. Lundbeck A/S
Inventor: Cheryl A. Grice , Olivia D. Weber , Daniel J. Buzard , Michael B. Shaghafi , John J. M. Wiener , Justin S. Cisar , Katharine K. Duncan
IPC: A61K31/4155 , A61K31/438 , A61K31/4439 , A61K31/496 , A61P25/00 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/048 , C07D491/08 , C07D519/00 , C07D498/08
Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
-
公开(公告)号:US12018004B2
公开(公告)日:2024-06-25
申请号:US18053582
申请日:2022-11-08
Applicant: H. Lundbeck A/S , THE SCRIPPS RESEARCH INSTITUTE
Inventor: Justin S. Cisar , Cheryl A. Grice , Todd K. Jones , Micah J. Niphakis , Jae Won Chang , Kenneth M. Lum , Benjamin F. Cravatt
IPC: C07D295/205 , A61P25/22 , C07C271/10 , C07C271/12 , C07D205/04 , C07D207/09 , C07D207/14 , C07D213/38 , C07D213/40 , C07D213/55 , C07D215/42 , C07D215/46 , C07D231/12 , C07D231/16 , C07D231/56 , C07D241/04 , C07D261/08 , C07D263/32 , C07D271/06 , C07D295/26 , C07D307/79 , C07D317/46 , C07D317/58 , C07D401/04 , C07D401/10 , C07D403/10 , C07D405/14 , C07D407/06 , C07D413/06 , C07D413/10 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107
CPC classification number: C07D295/205 , A61P25/22 , C07C271/10 , C07C271/12 , C07D205/04 , C07D207/09 , C07D207/14 , C07D213/38 , C07D213/40 , C07D213/55 , C07D215/42 , C07D215/46 , C07D231/12 , C07D231/16 , C07D231/56 , C07D241/04 , C07D261/08 , C07D263/32 , C07D271/06 , C07D295/26 , C07D307/79 , C07D317/46 , C07D317/58 , C07D401/04 , C07D401/10 , C07D403/10 , C07D405/14 , C07D407/06 , C07D413/06 , C07D413/10 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107
Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
-
公开(公告)号:US11530189B2
公开(公告)日:2022-12-20
申请号:US17195351
申请日:2021-03-08
Applicant: H. Lundbeck A/S , THE SCRIPPS RESEARCH INSTITUTE
Inventor: Justin S. Cisar , Cheryl A. Grice , Todd K. Jones , Micah J. Niphakis , Jae Won Chang , Kenneth M. Lum , Benjamin F. Cravatt
IPC: C07D295/205 , C07C271/12 , C07D317/46 , C07D317/58 , C07D231/12 , C07D231/16 , C07D231/56 , C07D241/04 , C07D471/04 , C07D471/10 , C07D261/08 , C07D487/04 , C07D263/32 , C07D205/04 , C07D491/107 , C07D207/14 , C07D271/06 , C07D307/79 , C07D405/14 , C07D215/42 , C07D213/40 , A61P25/22 , C07D295/26 , C07D213/55 , C07D401/04 , C07D407/06 , C07D413/06 , C07C271/10 , C07D207/09 , C07D213/38 , C07D215/46 , C07D401/10 , C07D403/10 , C07D413/10
Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
-
公开(公告)号:US11434222B2
公开(公告)日:2022-09-06
申请号:US17524632
申请日:2021-11-11
Applicant: H. LUNDBECK A/S
Inventor: John J. M. Wiener , Cheryl A. Grice , Daniel J. Buzard , Justin S. Cisar , Olivia Delene Weber , Amy Allan , Nicholas Raffaele , Jeanne Moody , Michael B. Shaghafi
IPC: C07D401/12 , C07D405/12 , C07D413/12 , C07F9/6558 , C07D401/14 , A61P25/04 , C07D487/04 , C07D471/04 , C07D417/12 , A61P25/08 , C07D221/20
Abstract: Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.5]octane-6-carboxylate compounds and pharmaceutical compositions comprising said compounds. The compounds and compositions provided herein are useful as inhibitors of MAGL. Furthermore, the compounds and compositions as provided herein are useful for the treatment of diseases and disorders benefiting from the inhibition of MAGL.
-
-
-